We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Safety and Efficacy of CAT-354

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00873860
First Posted: April 2, 2009
Last Update Posted: March 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
MedImmune LLC
April 1, 2009
April 2, 2009
August 26, 2016
February 23, 2017
March 24, 2017
June 2009
August 2010   (Final data collection date for primary outcome measure)
Change From Baseline in the Mean Asthma Control Questionnaire (ACQ) Score at Day 92 [ Time Frame: Day 1 and 92 ]
Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score is the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score.
To study the effect of CAT-354 on asthma control against placebo [ Time Frame: Study Day 92 ]
Complete list of historical versions of study NCT00873860 on ClinicalTrials.gov Archive Site
  • Time to First Observed Asthma Control [ Time Frame: Day 1 to Day 92 and Day 169 ]
    Time to first asthma control was defined as the number of days from Study Day 1 to the post-baseline ACQ score measurement time point when greater than or equal to (>=) 0.5 reduction from baseline in mean ACQ score was first observed. Time to first asthma control was analyzed from Day 1 through Day 92 and up to entire study duration through Day 169. The ACQ score is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score is the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled).
  • Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Recorded at Study Sites at Day 1, 15, 29, 43, 57, 71, 85, 92, 127 and 169 [ Time Frame: Day 1, 15, 29, 43, 57, 71, 85, 92, 127 and 169 ]
    Forced Expiratory Volume in 1 Second (FEV1) is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Spirometry was performed with the participant in the sitting/standing (kept consistent at each visit) position at study sites by the investigator or qualified designee according to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines. Multiple forced expiratory efforts (at least 3 but no more than 8) were performed for each office spirometry session and the 2 best efforts that met ATS/ERS acceptability and reproducibility criteria were recorded. The best efforts were based on the highest FEV1. The maximum FEV1 of the 2 best efforts was used for the analysis. Data collected on Day 1 prior to dosing was considered as baseline.
  • Change From Baseline in Peak Expiratory Flow (PEF) Recorded at Home Every Week From Day 1 to 169 [ Time Frame: Day -7 to 1 (predose), Day 2 to 169 ]
    The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Home peak flow testing for PEF was performed every morning while sitting or standing prior to using any medication (if needed) for asthma. Mean of the data was collected over 1 week prior to dosing on Day 1 was considered as baseline. Mean PEF values for each week were used to calculate the change from baseline values starting from Day 2 to 169.
  • Number of Puffs of Rescue Beta-2 Agonist Per Week [ Time Frame: Day -7 to 169 ]
    Number of Puffs of Rescue Beta-2 Agonist Per Week Rescue beta-2 agonist use (total number of puffs for the preceding week) was collected daily in the morning by the participants in the daily diary provided to them. Average values for each week were reported starting from Day -7 to Day 169.
  • Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Scores [ Time Frame: Day 1, 29, 57, 92, 127 and 169 ]
    Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]): a 32-item questionnaire that measures the functional impairments experienced by adult participants including 4 domains (Symptoms, Activity Limitations, Emotional Function, and Environmental Stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment).
  • Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Scores at Day 29, 57, 92, 127 and 169 [ Time Frame: Day 1, 29, 57, 92, 127 and 169 ]
    Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]): a 32-item questionnaire that measures the functional impairments experienced by adult participants including 4 domains (Symptoms, Activity Limitations, Emotional Function, and Environmental Stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data collected on Day 1 prior to dosing was considered as baseline
  • Patient Global Impression of Change (PGIC) [ Time Frame: Day 92 and 169 ]
    Patient Global Impression of Change (PGIC): participant rated instrument to measure participant's change in overall status compared to baseline on a 7-point scale; range from 1 (very much worse) to 7 (very much better).
  • Percentage of Participants With Mean Asthma Control Questionnaire (ACQ) Score Less Than or Equal to 0.75 or ACQ Score Greater Than 0.75 But Less Than 1.5 [ Time Frame: Day 92 and 169 ]
    Percentage of participants with mean Asthma Control Questionnaire (ACQ) score less than or equal to (<=) 0.75 or mean ACQ score greater than (>) 0.75 and less than (<) 1.5 were analyzed. The ACQ is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score is the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Mean ACQ scores of less than or equal to (<=) 0.75 indicated well-controlled asthma, mean ACQ scores greater than (>) 0.75 but less than (<) 1.5 indicated partly controlled asthma.
  • Serum Concentration for CAT-354 [ Time Frame: Predose on Day 15, 29, 43, 57, 71 and 85; Day 88, 92, 99, 127, and 169 ]
  • Number of Participants With Anti-Drug Antibodies to CAT-354 at Any Visit [ Time Frame: Day 1, 92 and 169 ]
  • Percentage of Participants With Positive Serum Antibodies to CAT-354 at Any Visit [ Time Frame: Day 1, 92 and 169 ]
  • Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) [ Time Frame: Day 1 to 169 ]
    An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and Day 169 that were absent before treatment or that worsened relative to pretreatment state.
  • Percentage of Participants With at Least 1 Moderate or Severe Exacerbation [ Time Frame: Day 92 and 169 ]
    Asthma exacerbation was defined as either a progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) or a reduction of >= 20 percent (%) in PEF or FEV1 from baseline that did not resolve after the initiation of rescue medications and resulted in an administration of systemic corticosteroids by the investigator or health care provider. Asthma exacerbation severity was classified as: 1) Moderate-worsening symptoms that required systemic corticosteroids. 2) Severe-worsening symptoms that required systemic corticosteroids and hospital admission.
  • Moderate or Severe Asthma Exacerbations Per Person Per Annum [ Time Frame: Day 1 to Day 92 and Day 169 ]
    Asthma exacerbation was defined as either a progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) or a reduction of >=20% in PEF or FEV1 from baseline that did not resolve after the initiation of rescue medications and resulted in an administration of systemic corticosteroids by the investigator or health care provider. Asthma exacerbation rate, calculated as total asthma exacerbations per person per annum, was assessed based on asthma exacerbation data up to Day 92 and 169 (Rate = mean asthma exacerbations for all participants/X days*365 days, where X = 92 or 169).
  • Time to First Moderate or Severe Asthma Exacerbation [ Time Frame: Day 1 to Day 92 and Day 169 ]
    Time to first moderate or severe asthma exacerbation was defined as time to first observed progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) or a reduction of >=20% in PEF or FEV1 from baseline that did not resolve after the initiation of rescue medications and resulted in an administration of systemic corticosteroids by the investigator or health care provider.
  • To study the effect of CAT-354 on the safety profile in this patient population. [ Time Frame: Study Day 92 and 169 ]
  • To study the effect of CAT-354 on the time to asthma control. [ Time Frame: Study Days 92 & 169 ]
  • To study the effect of CAT-354 on the mean percentage of subjects achieving a change from baseline ACQ score consistent with well controlled and partially controlled asthma [ Time Frame: Study Days 92 and 169 ]
  • To study the effect of SC CAT-354 on the time to first asthma exacerbation. [ Time Frame: Study Day 92 and 169 ]
  • To study the effect of SC CAT-354 on asthma exacerbation rates and severity (hospitalizations) [ Time Frame: Study Day 92 and 169 ]
  • To study the effect of SC CAT-354 on the variability of airflow obstruction using the parameters of forced volume within 1 second (FEV1) and peak expiratory flow (PEF) [ Time Frame: Study Day 92 and 169 ]
  • To study the effect of SC CAT-354 on a subject's requirement for concomitant asthma controller or rescue medications [ Time Frame: Study Day 92 and 169 ]
  • To study the effect of SC CAT-354 on patient reported outcomes including health-related quality of life using the Asthma Quality of Life Questionnaire with Standard Activities (AQLQ[S]) and the patient global impression of change [ Time Frame: Study Day 92 and 169 ]
  • To determine the pharmacokinetics and immunogenicity of SC CAT-354. [ Time Frame: Study Day 92 and 169 ]
Not Provided
Not Provided
 
Study to Evaluate the Safety and Efficacy of CAT-354
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Parallel-Arm, Multicenter Study to Evaluate the Efficacy and Safety of CAT-354, a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), on Asthma Control in Adults With Uncontrolled, Moderate-to-severe, Persistent Asthma
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel-arm study to evaluate the efficacy and safety of 3 subcutaneous (SC) treatment regimens of CAT-354 in adult subjects with uncontrolled, moderate-to-severe, persistent asthma.
Study MI-CP199, a Phase 2a, randomized, double-blind, placebo-controlled, parallel-arm, multicenter study will evaluate the effect of 3 SC treatment regimens of CAT-354 on asthma control in adults with uncontrolled, moderate-to-severe, persistent asthma.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Asthma
  • Other: Placebo
    Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
  • Biological: CAT-354 150 mg
    CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
    Other Name: Tralokinumab
  • Biological: CAT-354 300 mg
    CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
    Other Name: Tralokinumab
  • Biological: CAT-354 600 mg
    CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
    Other Name: Tralokinumab
  • Placebo Comparator: Placebo
    Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
    Intervention: Other: Placebo
  • Experimental: CAT-354 150 mg
    CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
    Intervention: Biological: CAT-354 150 mg
  • Experimental: CAT-354 300 mg
    CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
    Intervention: Biological: CAT-354 300 mg
  • Experimental: CAT-354 600 mg
    CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
    Intervention: Biological: CAT-354 600 mg

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
357
August 2010
August 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subjects
  • Age 18 to 65 years at the time of Screening
  • Subjects must have a body mass index (BMI) between 18 and 40 kilogram per square meter (kg/m^2)
  • Written informed consent obtained from the subject prior to performing any protocol related procedures, including Screening evaluations
  • Physician-diagnosed moderate-to-severe, persistent asthma requiring treatment with appropriate asthma controller medication
  • Shows forced expiratory volume in 1 second (FEV1) reversibility postbronchodilator of greater than or equal to (>=)12 percent and >=200 milliliter (mL) or have shown such values in a previous test within the last year, or have a positive airway hyperresponsiveness (AHR) test result in the last year
  • Pre-bronchodilator FEV 1 value >=40 percent of individual predicted value at Visits 1 and 3
  • Uncontrolled asthma consistent with Expert Panel Report (EPR)-3. In the 2 to 4 weeks preceding Screening, subjects should have a history of 1 or more of the following: Daytime asthma symptoms >=2 days/week, Nighttime awakening >=1 night/week, Salbutamol use >=2 days/week
  • An Asthma control questionnaire (ACQ) score >=1.5 at Visits 1 and 3
  • At least 1 occurrence of asthma exacerbation in the past year that required an unscheduled medical encounter
  • Men, unless surgically sterile, must likewise practice 2 effective methods of birth control (condom with spermicide) and must use such precautions from Day 1 through Study Day 169
  • Otherwise healthy by medical history and physical examination for that age group
  • A chest x-ray or computed tomography (CT) scan within the previous 12 months with no findings suggestive of acute or chronic respiratory pathology other than asthma
  • Ability and willingness to complete the follow-up period until Day 169 as required by the protocol.

Exclusion Criteria:

  • Known history of allergy or reaction to any component of the investigational product formulation
  • Acute illness other than asthma at the start of the study
  • History of an active infection within 4 weeks prior to Screening, or evidence of clinically significant active infection, including ongoing chronic infection
  • History of ingestion of untreated water in a location known to be infected with parasites, resulting in acute or chronic diarrhea; or a diagnosis of parasitic infection within 6 months prior to Screening
  • Use of immunosuppressive medication (except oral prednisone up to 10 milligram/day (mg/day) and inhaled and topical corticosteroids) within 30 days before randomization into the study
  • Receipt of immunoglobulin or blood products within 30 days before randomization into the study
  • Receipt of any investigational drug therapy or use of any biologicals including omalizumab within 6 months before the first dose of investigational product in this study or within 5 half-lives of an investigational agent or biologic, whichever is longer
  • History of any known immunodeficiency disorder
  • A positive hepatitis B surface antigen, or hepatitis C virus antibody
  • A positive human immunodeficiency virus test or is taking antiretroviral medications, as determined by medical history and/or subject's verbal report
  • A live or attenuated vaccination received within 4 weeks prior to Screening
  • Previous medical history, or evidence, of an intercurrent illness that may compromise the safety of the subject in the study
  • History of clinically significant abnormality on electrocardiogram (ECG) in the opinion of the investigator
  • Lactation (women)
  • History of treatment for alcohol or drug abuse within the past year
  • History suggestive of chronic obstructive pulmonary disease (COPD) and of cigarette smoking >=10 pack-years
  • Evidence of any systemic disease on physical examination
  • History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy less than or equal to (<=)1 year prior to Study Day 1 or other malignancies treated with apparent success with curative therapy <=5 years prior to entry
  • Known exposure to inhaled occupational agents or fumes
  • Any condition (eg, cystic fibrosis [CF] or COPD) that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of study results
  • Individuals who are legally institutionalized
  • Employees of the clinical study site or any other individuals involved with the conduct of the study, or family members of such individuals.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Bulgaria,   Germany,   Poland,   Romania,   United Kingdom
 
 
NCT00873860
MI-CP199
2008-007844-33 ( EudraCT Number )
No
Not Provided
Not Provided
MedImmune LLC
MedImmune LLC
Not Provided
Study Director: MedImmune LLC MedImmune LLC
MedImmune LLC
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP